Last reviewed · How we verify
neoadjuvant FOLFOXIRI
At a glance
| Generic name | neoadjuvant FOLFOXIRI |
|---|---|
| Sponsor | Chinese University of Hong Kong |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer (PHASE3)
- Colon Neoadjuvant FOLFOXIRI Study (PHASE2)
- FOLFOXIRI With or Without Intensification for Rectal Cancer (PHASE2)
- Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 (PHASE2)
- MFOLFOXIRI Plus PD-1 Inhibitor Vs MFOLFOX6 As Neoadjuvant Therapy for Locally Advanced Colon Cancer (PHASE2)
- Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy (PHASE3)
- Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- neoadjuvant FOLFOXIRI CI brief — competitive landscape report
- neoadjuvant FOLFOXIRI updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI